Bioatla Stock News

BioAlta shares have lost nearly three-quarters of their value over the past 3 years. Management has not done a good job of keeping lines of communication open and has a history of postponing clinical

BioAtla, Inc. (NASDAQ:BCAB ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - Pres

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther

BioAtla, Inc. (NASDAQ:BCAB ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors Jay Short - Chairman, CEO and Co-Founder Scott Smith - Preside

SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and

During the last session, BioAtla Inc. (NASDAQ:BCAB)’s traded shares were 0.63 million. At the end of the trading day, the stock’s price was $5.18, reflecting an intraday loss of -6.67% or -$0.37. The 52-week high for the BCAB share is $76.63, that puts it down -1379.34 from that peak though still a striking 0.97% gain … BioAtla Inc. (NASDAQ: BCAB) Stock: Boom Or Bust? What Happens Next? Read More »

BioAtla press release (BCAB): Q4 Net loss was $23.4M compared to a net loss of $16.4M for the same quarter in 2020.Cash and cash equivalents as of December 31, 2021 were $245M.

BioAtla Inc (BCAB) shares closed this week 21.7% lower than it did at the end of last week. The stock is currently down 35.7% year-to-date, down 72.2% over the past 12 months, and down 59.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $16.49 and as low as $11.96 this week.Shares closed 83.5% below its 52-week high and 5.6% above its 52-week low.Trading volume this week was 38.9% higher than the 10-day average and 98.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 5833.8% The company's stock price performance over the past 12 months lags the peer average by 373.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

BioAtla Inc (BCAB) shares closed today at 0.9% above its 52 week low of $13.79, giving the company a market cap of $491M. The stock is currently down 29.1% year-to-date, down 65.9% over the past 12 months, and down 55.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 148.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 5278.1% The company's stock price performance over the past 12 months lags the peer average by 312.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid…

BioAtla (BCAB) has added ~3.1% in the post-market after the company announced a clinical collaboration with Bristol Myers Squibb (BMY) to study its lead candidates BA3011 and BA3021

SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical…

BioAtla Inc (BCAB) shares closed today at 0.3% above its 52 week low of $18.72, giving the company a market cap of $693M. The stock is currently flat year-to-date, down 42.3% over the past 12 months, and down 36.7% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.9%. Trading Activity Trading volume this week was 7.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months lags the peer average by 35.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.